Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
117 Lu-DGUL by Cellbion for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
117 Lu-DGUL is under clinical development by Cellbion and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According...